UniProtKB/Swiss-Prot Q12913 : Variant p.Glu872Asp
Receptor-type tyrosine-protein phosphatase eta
Gene: PTPRJ
Feedback ?
Variant information
Variant position:
872
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Glutamate (E) to Aspartate (D) at position 872 (E872D, p.Glu872Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are medium size and acidic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
872
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
1337
The length of the canonical sequence.
Location on the sequence:
VILTTGEAGHPSADVLKYTY
E DFKKGASDTYVTYLIRTEEK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human V-ILTTGEAGHPSADVLKYTYE DFKKGASDTYVTYLIRTEEK
Mouse V-ILTTGEAAQPSADVLKYTYE DFKRGASDTYVTYLIRIEE
Chicken VMIVTEAEGCLPSKSDLDYTYN DFKQKMTATYVTYVIDVEE
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
36 – 1337
Receptor-type tyrosine-protein phosphatase eta
Topological domain
36 – 975
Extracellular
Domain
816 – 902
Fibronectin type-III 9
Alternative sequence
540 – 1337
Missing. In isoform 2.
Literature citations
Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density.
Oestman A.; Yang Q.; Tonks N.K.;
Proc. Natl. Acad. Sci. U.S.A. 91:9680-9684(1994)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT ASP-872;
Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta.
Honda H.; Inazawa J.; Nishida J.; Yazaki Y.; Hirai H.;
Blood 84:4186-4194(1994)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT ASP-872;
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
Ruivenkamp C.A.L.; van Wezel T.; Zanon C.; Stassen A.P.M.; Vlcek C.; Csikos T.; Klous A.M.; Tripodis N.; Perrakis A.; Boerrigter L.; Groot P.C.; Lindeman J.; Mooi W.J.; Meijjer G.A.; Scholten G.; Dauwerse H.; Paces V.; van Zandwijk N.; van Ommen G.J.B.; Demant P.;
Nat. Genet. 31:295-300(2002)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-1337; VARIANTS CYS-214; PRO-276 AND ASP-872;
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
Iuliano R.; Le Pera I.; Cristofaro C.; Baudi F.; Arturi F.; Pallante P.; Martelli M.L.; Trapasso F.; Chiariotti L.; Fusco A.;
Oncogene 23:8432-8438(2004)
Cited for: VARIANTS PRO-276; GLN-326 AND ASP-872;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.